4/5, 2:34 PM (Source: TeleTrader)
more TeleTrader news

Vir, GSK's treatment works against California COVID strain

Vir Biotechnology Inc. and GlaxoSmithKline plc (GSK) claimed on Monday that their coronavirus antibody treatment remains effective versus the COVID-19 strain initially detected in California.

Data obtained through new preclinical research hinted that the antibody treatment called VIR-7831 could be utilized in combating the California variant, due to the strain's ability to "confer some degree of resistance to vaccines and [convalescent plasma] antibody therapies," the statement read. It added that VIR-7831 targets a different part of the virus's protein, thus providing more substantial protection from its variations.

"These data add to the growing body of evidence supporting our rationale for targeting a non-RBM epitope and the potential of VIR-7831 to combat the current variants of concern, including the evasive California variant, either as monotherapy or as a foundational therapy for future combinations," Vir CEO George Scangos concluded.

Vir's shares jumped 3.47% in the premarket, selling for $51.29, while GSK moved up by 0.36%, to go for $35.95.

Breaking the News / BU